Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

S. Patel,S. Zhao,L. Wei,M. Li,E. Bertino,C. Presley,M. Welliver,K. Haglund,J. Palmer,A. Arnett,S. Beyer, E. Mende,J. Elder,D. Hardesty,P. Shields,D. Carbone,G. Otterson,T. Williams,D. Owen

Journal of Thoracic Oncology（2021）

Cited 1|Views13
No score
Abstract
The addition of consolidation durvalumab after concurrent chemo-radiation has demonstrated an improvement in progression-free and overall survival in patients with unresectable stage III NSCLC. In an updated analysis of PACIFIC Study, 6.3% of patients who were treated with durvalumab developed brain metastasis (BMets). We did this study to further evaluate the incidence and treatment of BMets.
More
Translated text
Key words
Stage III NSCLC, Brain Metastasis, Durvalumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined